Therapeutic Glaucoma

Most patients do well on topical therapy, but innovation in IOP-lowering drops remains essential.

Glaukos noted under the updated labeling, physicians may now re-administer iDose TR more than once in patients who maintain a healthy cornea, as defined by corneal endothelial cell density parameters.

James Tsai, MD, MBA, sheds light on what is in the offing for glaucoma specialists

The Bimatoprost Drug Pad-IOL System is intended for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Bimatoprost ophthalmic solution 0.01% is a prostaglandin analog for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension and is the generic equivalent of LUMIGAN.

Travoprost is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

This update from UHC includes procedures enabled with its OMNI Surgical System technology from Sight Sciences.

The study will be evaluating the safety, tolerability, and efficacy of QLS-111 in adult patients with normal tension glaucoma.

NCX 470 met the primary endpoint of non-inferiority in lowering intraocular pressure (IOP) from baseline compared to the standard of care, latanoprost 0.005%.

PA5108 is a rod-shaped, biodegradable microimplant designed to significantly reduce IOP in patients with primary open-angle glaucoma consistently over 6 months.

Nicox and Kowa entered into an agreemen in February 2024, in which Kowa was granted exclusive Japanese rights to develop and commercialize NCX 470.

Eyetronic is a noninvasive treatment for glaucoma that provides external neural stimulation to the optic nerve of patients.

Under the terms of the agreement, Kowa receives exclusive rights to develop and commercialize NCX 470 in the US and all other territories of the world excluding Japan, China, Korea, and Southeast Asia.

Funding will support the continued clinical advancement of its lead ocular implant candidate, PA5108, for the reduction of IOP in patients with ocular hypertension and glaucoma.

Weighing the benefits and trade-offs of preserved versus preservative-free glaucoma treatments is key to optimizing long-term patient care.

NCX 470, Nicox’s lead clinical product candidate, is a novel NO-donating bimatoprost eye drop with a dual mechanism of action (nitric oxide and prostaglandin analogue).

Tapcom is a preservative-free, fixed-combination eye drop of tafluprost 0.0015% and timolol 0.5% for lowering intraocular pressure.

The novel nitric oxide-donating bimatoprost eye drop is being clinically developed for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension.

The bio-interventional platform is for uveoscleral outflow enhancement in open-angle glaucoma patients undergoing combined cataract surgery.

A survey conducted by the Preservative Freedom Coalition, asked 558 patients with glaucoma or ocular hypertension how they felt about their treatments, the future of their eye health, trust in their doctors and more.

The iDose platform is designed to address ubiquitous patient non-adherence and chronic side effects associated with topical medications by providing 24/7 release of medication.

According to Iridex Corp., the study confirms MicroPulse TLT's sustained safety and efficacy in managing glaucoma, reducing intraocular pressure and medication reliance with minimal complications over 5 years.

According to the partners, glaucoma research to be led by internationally renowned glaucoma surgeon Ike Ahmed, MD, FRCSC, distinguished research scientist Fiona McDonnell, PhD, and Ian Pitha, MD, PhD, associate director of the Alan S. Crandall Center for Glaucoma Innovation

According to researchers, GPT-4o demonstrates potential in generating comprehensive differential glaucoma diagnoses but falls short in primary diagnostic accuracy, underscoring its role as a complementary tool rather than a standalone diagnostic solution.

PolyActiva’s phase 2 clinical trial of its PA5108 glaucoma implant met efficacy and safety end points, demonstrating more than 20% reduction in IOP. The biodegradable implant offers sustained drug delivery for up to 26 weeks, addressing challenges of patient adherence and improving glaucoma treatment outcomes.